Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul;23(3):553-567.
doi: 10.1007/s10238-022-00887-0. Epub 2022 Sep 15.

The new progress in cancer immunotherapy

Ajmeri Sultana Shimu #  1 , Hua-Xing Wei #  2 , Qiangsheng Li  1 , Xucai Zheng  3 , Bofeng Li  4
Affiliations
Review

The new progress in cancer immunotherapy

Ajmeri Sultana Shimu et al. Clin Exp Med. 2023 Jul.

Abstract

The cross talk between immune and non-immune cells in the tumor microenvironment leads to immunosuppression, which promotes tumor growth and survival. Immunotherapy is an advanced treatment that boosts humoral and cellular immunity rather than using chemotherapy or radiation-based strategy associated with non-specific targets and toxic effects on normal cells. Immune checkpoint inhibitors and T cell-based immunotherapy have already exhibited significant effects against solid tumors and leukemia. Tumor cells that escape immune surveillance create a major obstacle to acquiring an effective immune response in cancer patients. Tremendous progress had been made in recent years on a wide range of innate and adaptive immune checkpoints which play a significant role to prevent tumorigenesis, and might therefore be potential targets to suppress tumor cells growth. This review aimed to summarize the underlying molecular mechanisms of existing immunotherapy approaches including T cell and NK-derived immune checkpoint therapy, as well as other intrinsic and phagocytosis checkpoints. Together, these insights will pave the way for new innate and adaptive immunomodulatory targets for the development of highly effective new therapy in the future.

Keywords: Cancer; Immune checkpoint; Immunotherapy; NK cells; SIRP-α; Siglec.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Inhibitory and stimulatory receptors on APC/T cells and tumor cells
Fig. 2
Fig. 2
The interaction between NK cells and tumor cells
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Whiteside TL. Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol. 2006;16(1):3–15. - PubMed
    1. Harris, T. J.; Drake, C. G., Primer on tumor immunology and cancer immunotherapy. J Immuno Therapy Cancer 2013, 1. - PMC - PubMed
    1. Seledtsov VI, Goncharov AG, Seledtsova GV. Multiple-purpose immunotherapy for cancer. Biomed Pharmacother. 2015;76:24–29. - PubMed
    1. Tian T, Olson S, Whitacre JM, Harding A. The origins of cancer robustness and evolvability. Integr Biol. 2011;3(1):17–30. - PubMed
    1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. - PMC - PubMed

LinkOut - more resources